STOCK TITAN
  1. Home
  2. News
  3. SLNO

Soleno Therapeutics (SLNO) Stock News

SLNO Nasdaq

Welcome to our dedicated page for Soleno Therapeutics news (Ticker: SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.

Soleno Therapeutics develops and commercializes novel therapeutics for rare diseases, centered on VYKAT XR (diazoxide choline) extended-release tablets for hyperphagia in adults and children 4 years and older with Prader-Willi syndrome. News about SLNO commonly covers the U.S. commercial launch of VYKAT XR, operating and financial results, prescriber and patient-access metrics, and clinical publications tied to the DCCR development program.

Company updates also include regulatory matters for diazoxide choline, corporate finance actions, executive and governance changes, investor conference participation, and securities-litigation notices involving product-safety and disclosure allegations.

News

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News

Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
-
News

Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
News

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
private placement offering
-
News

Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.48%
Tags
private placement offering
-
News

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.48%
Tags
private placement offering
News

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
504.97%
Tags
none
-
News

Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
conferences
-
News

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
management
News

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
earnings

FAQ

What is the current stock price of Soleno Therapeutics (SLNO)?

The current stock price of Soleno Therapeutics (SLNO) is $53.01 as of May 18, 2026.

What is the market cap of Soleno Therapeutics (SLNO)?

The market cap of Soleno Therapeutics (SLNO) is approximately 2.8B.